Novartis said on Tuesday it was taking its experimental medicine ligelizumab to late-stage trials after the drug showed signs of outperforming existing product Xolair in treating severe urticaria, also known as hives.
from Reuters: Health News https://ift.tt/2zFpISW
via
IFTTT
0 comments:
Post a Comment